Correlation Between Dgb Financial and Sk Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both Dgb Financial and Sk Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dgb Financial and Sk Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Dgb Financial and Sk Biopharmaceuticals Co, you can compare the effects of market volatilities on Dgb Financial and Sk Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dgb Financial with a short position of Sk Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dgb Financial and Sk Biopharmaceutica.

Diversification Opportunities for Dgb Financial and Sk Biopharmaceutica

-0.58

Correlation Coefficient

Dgb Financial  Sk Biopharmaceutica

Excellent diversification

The 3 months correlation between Dgb and 326030 is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Dgb Financial and Sk Biopharmaceuticals Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sk Biopharmaceuticals and Dgb Financial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dgb Financial are associated (or correlated) with Sk Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sk Biopharmaceuticals has no effect on the direction of Dgb Financial i.e., Dgb Financial and Sk Biopharmaceutica go up and down completely randomly.

Pair Corralation between Dgb Financial and Sk Biopharmaceutica

Assuming the 90 days trading horizon Dgb Financial is expected to under-perform the Sk Biopharmaceutica. But the stock apears to be less risky and, when comparing its historical volatility, Dgb Financial is 1.76 times less risky than Sk Biopharmaceutica. The stock trades about -0.04 of its potential returns per unit of risk. The Sk Biopharmaceuticals Co is currently generating about 0.33 of returns per unit of risk over similar time horizon. If you would invest  9,690,000  in Sk Biopharmaceuticals Co on October 10, 2024 and sell it today you would earn a total of  1,940,000  from holding Sk Biopharmaceuticals Co or generate 20.02% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Dgb Financial  vs.  Sk Biopharmaceuticals Co

Dgb Financial

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Dgb Financial are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Dgb Financial is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Sk Biopharmaceuticals

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Sk Biopharmaceuticals Co are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Sk Biopharmaceutica may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Dgb Financial and Sk Biopharmaceutica

The main advantage of trading using opposite Dgb Financial and Sk Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dgb Financial position performs unexpectedly, Sk Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will offset losses from the drop in Sk Biopharmaceutica's long position.

The idea behind Dgb Financial and Sk Biopharmaceuticals Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.